Também conhecido como
Activated Partial Thromboplastin Time
aPTT
APTT
Nome formal
Partial Thromboplastin Time
Este artigo foi revisto pela última vez em
Este artigo foi modificado pela última vez em
23 de Abril de 2018.
At a Glance
Why Get Tested?
As part of an investigation of a bleeding or thrombotic episode; to monitor unfractionated (standard) heparin anticoagulant therapy
When To Get Tested?
When you have unexplained bleeding or blood clotting; when you are on unfractionated (standard) heparin anticoagulant therapy; sometimes as part of a pre-surgical screen
Sample Required?
A blood sample drawn by needle from a vein in the arm
What is being tested?
The partial thromboplastin time (PTT) test measures the functionality of the intrinsic and common pathways of the coagulation cascade. When a person starts bleeding, the body uses the coagulation cascade to produce blood clots to seal off injuries to blood vessels, to prevent further blood loss and to give the damaged areas time to heal. The cascade consists of a group of coagulation factors produced in the liver. These proteins are activated sequentially along either the extrinsic (tissue-related) or intrinsic (blood vessel-related) pathways. The branches of the pathway then come together into the common pathway and complete their task with the formation of a stable blood clot.

Each component of the coagulation cascade must be functioning properly and be present in sufficient quantity for normal blood clot formation. If there is an inherited or acquired deficiency in one or more of the factors, or if the factors are functioning abnormally, then stable clot formation will be inhibited and excessive bleeding and/or clotting may occur.

The PTT test measures the length of time that it takes for clotting to occur in a test tube when reagents (chemicals) are added to plasma. When the sample takes longer than normal to clot, the PTT is said to be “prolonged.”

How is the sample collected for testing?

A blood sample is obtained by inserting a needle into a vein in the arm.
Accordion Title
Common Questions
  • How is it used?
    The PTT test is ordered when someone has unexplained bleeding or clotting. Along with the PT (which evaluates the extrinsic and common pathways of the coagulation cascade), the PTT is often used as a starting place when investigating the cause of a bleeding or thrombotic episode. It may be ordered as part of a panel of sequential tests that is used to look for Lupus anticoagulant to help investigate the cause of recurrent miscarriages, especially when they occur in the second or third trimester. The PTT and PT tests are sometimes used as pre-surgical screens for bleeding tendencies, although numerous studies have shown that they are not generally useful for this purpose.

    The PTT is also ordered at intervals to monitor unfractionated (standard) heparin anticoagulant therapy. Heparin is a drug that is given intravenously (IV) or by injection to prevent and to treat thromboemboli. When it is given in therapeutic doses, it must be closely monitored. If given too much, the patient may bleed excessively; too little and the patient may continue to clot. In some cases, heparin can unintentionally decrease a patient’s platelet count in a complication called heparin-induced thrombocytopenia. When this occurs, substitute anticoagulants such as hirudin or argatroban may be given. The PTT test is also used to monitor these therapies. It does not directly measure the anticoagulants used but measures their effect on blood clotting.

    If the PTT is prolonged and the cause is not anticoagulant therapy, heparin contamination, or other pre-analytical problems such as an insufficient or clotted blood sample, then the PTT is followed by mixing studies to check for possible coagulation factor deficiencies or inhibitors. The patient’s plasma is mixed with pooled normal plasma (a combination of blood from different donors that has normal amounts of all of the clotting factors). If the patient has a factor deficiency, mixing their plasma with pooled normal plasma should provide enough of the missing factor(s) for the PTT to “correct” (clot within the normal time frame). If it does correct, further coagulation factor testing is done to determine those factors that are deficient. If it does not correct, then the prolonged PTT may be due to a specific or nonspecific inhibitor. Further testing may then be done to check for antibodies to specific factors and to identify nonspecific antibodies, such as lupus anticoagulant and anticardiolipin antibodies.

  • When is it ordered?
    The PTT may be ordered, along with other tests such as a PT, when a patient presents with unexplained bleeding or bruising, a thromboembolism, an acute condition such as disseminated intravascular coagulation (DIC) that may cause both bleeding and clotting as factors are used up at a rapid rate, or with a chronic condition such as liver disease. When the patient has had a thrombotic episode or recurrent miscarriages, the PTT may be ordered as part of an evaluation for lupus anticoagulant or anticardiolipin antibodies.

    It may be ordered as part of a pre-surgical evaluation for bleeding tendencies, especially if the surgery carries an increased risk of blood loss and/or if the patient has a clinical history of bleeding, such as nosebleeds and bruising, that may indicate the presence of an inherited or acquired factor deficiency or of an acquired inhibitor.

    When a patient is on intravenous (IV) or injection heparin therapy, the PTT is ordered at regular intervals to monitor the degree of anticoagulation. When a person is switched from heparin therapy to longer-term warfarin (Coumadin) therapy, the two are overlapped and both the PTT and PT are monitored until the patient has stabilized.

    PTT is not useful in monitoring anticoagulant therapy using low-molecular weight heparin.

  • What does the test result mean?
    Normal PTTs may reflect normal clotting function, but moderate single factor deficiencies may still exist. They will not be reflected in the PTT until they have decreased to 30% to 40% of normal. Also lupus anticoagulant may be present but may not prolong the PTT result. If the lupus anticoagulant (LA) is suspected, an LA-sensitive PTT can be used to test for it.

    A decreased PTT may result when coagulation factor VIII is elevated. This may occur during an acute phase reaction, a condition causing acute tissue inflammation or trauma. This is usually a temporary change that is not monitored with the PTT. When the condition causing the acute phase reaction is resolved, the PTT will return to normal.

    A prolonged PTT means that clotting is taking longer to occur than expected and may be caused by a variety of factors (see the list below). Often, this suggests that there may be a coagulation factor deficiency or a specific or nonspecific inhibitor affecting the body’s clotting ability. Coagulation factor deficiencies may be acquired or inherited. Several factors are Vitamin K dependent. If a person has liver disease, for instance, or more rarely a Vitamin K deficiency, he may have one or more factor deficiencies. Inherited factor deficiencies may affect the quantity and/or function of the factor produced.

    Inhibitors may be antibodies that specifically target certain coagulation factors, such as Factor VIII antibodies, or they may be non-specific inhibitors, such as lupus antocoagulant and anticardiolipin antibodies that bind to chemicals called phospholipids found on the surface of platelets. Since phospholipids assist in the clotting process, and since the PTT test reagents (chemicals used to run the tests) contain phospholipids, such antibodies may prolong the PTT even though they are usually associated with thrombosis instead of bleeding.

    The administration of heparin will also prolong PTT, either as part of anticoagulation therapy or as a contaminant.

    Prolonged PTT tests may be due to:

    1. Pre-analytical problems. These may include:
      • Insufficient sample - there must be enough blood collected. The anticoagulant to blood ratio must be 9:1 in the collection tube.
      • Patients with high hematocrit levels may have prolonged PTTs.
      • Heparin contamination. This is the most common problem, especially when blood is collected from intravenous lines that are being kept “open” with heparin washes.
      • Clotted blood samples - the clotting process uses up some of the factors.
    2. Inherited or acquired factor deficiencies. Some factor deficiencies cause bleeding while others, called contact factors, prolong the PTT in vitro but do not cause bleeding and have little clinical significance. Prolonged PTTs due to factor deficiencies usually “correct” after being mixed with pooled normal plasma. PTT may be prolonged in von Willebrand’s disease.
    3. A nonspecific inhibitor such as the lupus anticoagulant (LA). If the LA does prolong the PTT or LA sensitive PTT, it will not correct with normal plasma mixing, but it will usually correct if an excess of phospholipid is added to the sample.
    4. A specific inhibitor. Although these are relatively rare, these are antibodies that attack a particular factor. They may develop in someone with a bleeding disorder who is receiving factor replacements (such as Factor VIII, which is used to treat hemophilia A) or spontaneously as an autoantibody. The specific inhibitor will prolong the PTT and it will not correct with mixing.
    5. Heparin anticoagulant therapy (the target PTT is often about 1.5 to 2.5 times higher than a patient’s pretreatment level).
    6. Warfarin (Coumadin) anticoagulation therapy. The PTT is not used to monitor warfarin therapy, but it may be affected by it.
    7. Prolonged PTT levels may also be seen with leukemia.
  • Is there anything else I should know?
    Once heparin therapy is started, the laboratory work-up of an abnormal PTT is difficult. Often, when a patient presents with unexplained bleeding or clotting, a PTT will be ordered along with other bleeding and hypercoaguability tests before treatment is begun. If this is not feasible, some investigational testing may have to wait until the current acute condition has been resolved.

    Other testing that may be done along with a PTT includes:
  • Platelet counts – which should always be monitored during heparin therapy to promptly detect any heparin-induced thrombocytopenia
  • Thrombin time testing – this is sometimes ordered to help rule out heparin contamination
  • Fibrinogen testing - this may be done to rule out hypofibrinogenemia as a cause of PTT prolongation.
  • Patients should avoid high-fatty meals prior to having their blood drawn for a PTT.

  • Is the PTT always used to monitor heparin therapy?
    In a couple of situations, it is not. 1) When very high doses of heparin are used, as may occur during open heart surgery, the PTT loses its sensitivity; it will not clot. At this intense level of anticoagulation the Activated Clotting Time (ACT) is used as a monitoring tool instead of PTT. 2) Low molecular weight heparin (LMWH), which is a fast-acting form of heparin used in other treatment applications (such as deep vein thrombosis prevention), does not usually require monitoring.
  • Should everyone have their PTT checked?
    This is not usually necessary. The PTT is not used as a routine general screening test. It is ordered when someone has symptoms of abnormal bleeding or clotting. Asymptomatic patients are occasionally screened prior to a surgery if their doctor feels that it will help evaluate their risk of excessive bleeding during the procedure.
  • How can I change my PTT?
    The PTT is not something you can change through lifestyle changes (unless perhaps if you have a Vitamin K induced factor deficiency). It is a reflection of the integrity of your clotting system. If your PTT is prolonged due to acquired factor deficiencies, then addressing the underlying condition may bring the results to near normal levels. If they are prolonged due to a temporary or acute condition, they should return to normal on their own within a short time period.
  • View Sources
    S1
    Thomas, Clayton L., Editor (1997). Taber’s Cyclopedic Medical Dictionary. F.A. Davis Company, Philadelphia, PA [18th Edition].

    S2
    Pagana, Kathleen D. & Pagana, Timothy J. (2001). Mosby’s Diagnostic and Laboratory Test Reference 5th Edition: Mosby, Inc., Saint Louis, MO.

    S3
    (2002 November 19, Modified). Activated Partial Thromboplastin Time [30 paragraphs]. Mass Gen. Hospital Pathology Service Laboratory Medicine [On-line information, Coag Test Handbook]. Available FTP: http://www.mgh.harvard.edu/labmed/lab/coag/handbook/co003400.htm#co003400

    S4
    Activated Partial Thromboplastin Time [10 paragraphs]. MCL Web Resources, Topics in Hemostasis [On-line information]. Available FTP: http://155.58.145.40/hemostasis/PTT1.html

    S5
    Olson, J. (1999 September). Addressing clinical etiologies of a prolonged aPTT [32 paragraphs]. CAP Today, In the News [On-line Newsletter]. Available FTP: http://www.cap.org/captoday/CaseStudy/coag4.html

    S6
    Activated Partial Thromboplastin Time [7 paragraphs]. Florida Hospital Cancer Institute, Clinical and Research Laboratories Coagulation Test Panels [On-line information]. Available FTP: http://www.fhci-labs.com/researchlabs/clinicallabs/hemostasisandthrombosis/panels.htm

    S7
    PTT-LA [7 paragraphs]. Florida Hospital Cancer Institute, Clinical and Research Laboratories Coagulation Test Panels [On-line information]. Available FTP: http://www.fhci-labs.com/researchlabs/clinicallabs/hemostasisandthrombosis/panels.htm

    S8
    Duke University Medical Center Clinical Coagulation Laboratory Coagulation Test Descriptions [On-line information]. Available FTP: http://pathology.mc.duke.edu/coag/TestDes.htm

    S9
    Elstrom, R. (2001 November 25, Updated ). PTT [14 paragraphs]. MEDLINEplus Health Information, Medical Encyclopedia [On-line information]. Available FTP: http://www.nlm.nih.gov/medlineplus/ency/article/003653.htm

    S10
    Coagulation Test Panels [9 paragraphs]. Clinical and Research Laboratories, Florida Hospital Cancer Institute [On-line information]. Available FTP: http://www.fhci-labs.com/researchlabs/clinicallabs/hemostasisandthrombosis/panels.htm

    S11
    Menta, S. (1999 Spring). The Coagulation Cascade [148 paragraphs]. Physiology Disorders Evaluation, College of Medicine, Univ of Florida [On-line information]. Available FTP: http://www.medinfo.ufl.edu/year2/coag/title.html

    S12
    Elstrom, R. (2001 November 25, Updated). PT [18 paragraphs]. MEDLINEplus Health Information, Medical Encyclopedia [On-line information]. Available FTP: http://www.nlm.nih.gov/medlineplus/ency/article/003652.htm

    S13
    Elstrom, R. (2001 November 25, Updated). PTT [14 paragraphs]. MEDLINEplus Health Information, Medical Encyclopedia [On-line information]. Available FTP: http://www.nlm.nih.gov/medlineplus/ency/article/003653.htm

    S14
    What is a Bleeding Disorder? [10 paragraphs]. National Hemophilia Foundation, Bleeding Disorders Info Center [On-line information]. Available FTP: http://www.hemophilia.org/bdi/bdi_general.htm

    S15
    DeLoughery, T. (1999 March 15). Tests of Hemostasis and Thrombosis [66 paragraphs]. OHSU [Online student handout]. Available FTP: http://www.ohsu.edu/som-hemonc/handouts/deloughery/printtest.html

    S16
    Pagana, Kathleen D. & Pagana, Timothy J. (© 2007). Mosby’s Diagnostic and Laboratory Test Reference 8th Edition: Mosby, Inc., Saint Louis, MO. Pp 705-707.

    S17
    Clarke, W. and Dufour, D. R., Editors (2006). Contemporary Practice in Clinical Chemistry, AACC Press, Washington, DC. Harris, N. et. al. Chapter 19: Assessment of Hemostasis in the Clinical Laboratory. pp 227-239.